Efficacy of DYRK1A Inhibitors in Novel Models of Down Syndrome Acute Lymphoblastic Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2024 Mar 1

PMID 38426275

Authors

Shannon L Carey-Smith

Maryam H Simad

Kunjal Panchal

Carlos Aya-Bonilla

Hannah Smolders

Sang Lin

Jesse D Armitage

Vivien T Nguyen

Kathryn Bentley

Jette Ford

Sajla Singh

Joyce Oommen

Anouchka P Laurent

Thomas Mercher

John D Crispino

Andrew P Montgomery

Michael Kassiou

Thierry Besson

Emmanuel Deau

Laurent Meijer

Laurence C Cheung

Rishi S Kotecha

Sebastien Malinge

Affiliations

Soon will be listed here.

Citing Articles

Novel Thiazole-Fused [4,5-] or [5,4-]Quinazolin-8-ones and Their Quinazoline Analogues: Synthesis and Biological Evaluation.

Broudic N, Pacheco-Benichou A, Corbiere C, Baratte B, Robert T, Bach S Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598364 PMC: 11597202. DOI: 10.3390/ph17111452.

A transgenic mouse model of Down syndrome acute lymphoblastic leukemia identifies targetable vulnerabilities.

Junco J, Rochette M, Alozie M, Rashid R, Terrell M, Zorman B Haematologica. 2024; 109(12):4083-4088.

PMID: 39049603 PMC: 11609804. DOI: 10.3324/haematol.2023.284761.

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.

Carey-Smith S, Kotecha R, Cheung L, Malinge S Int J Mol Sci. 2024; 25(13).

PMID: 38999925 PMC: 11241182. DOI: 10.3390/ijms25136815.

Aberrant stem cell and developmental programs in pediatric leukemia.

Ling R, Cross J, Roy A Front Cell Dev Biol. 2024; 12:1372899.

PMID: 38601080 PMC: 11004259. DOI: 10.3389/fcell.2024.1372899.

References

Zhou Q, Phoa A, Abbassi R, Hoque M, Reekie T, Font J . Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. J Med Chem. 2017; 60(5):2052-2070. DOI: 10.1021/acs.jmedchem.6b01840. View

Page E, Heatley S, Eadie L, McClure B, de Bock C, Omari S . HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene. 2021; 41(6):797-808. DOI: 10.1038/s41388-021-02126-4. View

Laetsch T, Maude S, Balduzzi A, Rives S, Bittencourt H, Boyer M . Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022; 36(6):1508-1515. DOI: 10.1038/s41375-022-01550-z. View

Li Z, Chang T, Junco J, Devidas M, Li Y, Yang W . Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023; 142(2):172-184. PMC: 10352600. DOI: 10.1182/blood.2023019765. View

Tahtouh T, Durieu E, Villiers B, Bruyere C, Nguyen T, Fant X . Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors. J Med Chem. 2021; 65(2):1396-1417. DOI: 10.1021/acs.jmedchem.1c01141. View

Lane A, Chapuy B, Lin C, Tivey T, Li H, Townsend E . Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014; 46(6):618-23. PMC: 4040006. DOI: 10.1038/ng.2949. View

ODoherty A, Ruf S, Mulligan C, Hildreth V, Errington M, Cooke S . An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science. 2005; 309(5743):2033-7. PMC: 1378183. DOI: 10.1126/science.1114535. View

Lindberg M, Deau E, Miege F, Greverie M, Roche D, George N . Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate. J Med Chem. 2023; 66(23):15648-15670. DOI: 10.1021/acs.jmedchem.3c01888. View

Buitenkamp T, Izraeli S, Zimmermann M, Forestier E, Heerema N, van den Heuvel-Eibrink M . Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2013; 123(1):70-7. PMC: 3879907. DOI: 10.1182/blood-2013-06-509463. View

10.

Bhansali R, Rammohan M, Lee P, Laurent A, Wen Q, Suraneni P . DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021; 131(1). PMC: 7773384. DOI: 10.1172/JCI135937. View

11.

Laurent A, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S . Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. Clin Cancer Res. 2020; 26(13):3307-3318. PMC: 7334063. DOI: 10.1158/1078-0432.CCR-19-3519. View

12.

Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C . Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol. 2013; 162(1):98-106. DOI: 10.1111/bjh.12348. View

13.

Rafei H, Kantarjian H, Jabbour E . Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2019; 188(2):207-223. DOI: 10.1111/bjh.16207. View

14.

Rabin K, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler J . Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2023; 42(2):218-227. PMC: 10824380. DOI: 10.1200/JCO.23.00389. View

15.

Ceppi F, Stephens D, den Hollander B, Krueger J, Whitlock J, Sung L . Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016; 63(11):1949-53. DOI: 10.1002/pbc.26127. View